Actinogen Medical Limited (ACW.AX)
- PR Newswire
FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial
Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to proceed with its six-month, Phase 2b, placebo-controlled clinical trial of Xanamem in patients with early stages of Alzheimer's Disease (AD).
- PR Newswire
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
Actinogen Medical Limited (ASX: ACW) is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression clinical trial that will measure the effects of Xanamem on safety, cognitive performance and depression in patients who are inadequately treated by their anti-depressant medication and have both depressive symptoms and cognitive impairment.
- PR Newswire
Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer's Disease (AD) patients
Actinogen Medical Limited (ASX: ACW) today announces positive Phase 2a clinical data from its Alzheimer's Disease (AD) biomarker study, which validates the Company's planned Xanamem program in AD.
